Michael Rothkopf

Dr. Michael Rothkopf

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in BMJ Nutrition, Prevention & Health
Verified
Journal Article
Open access
PDF file
MRMichael Rothkopf
Michael Rothkopf
MPMohan Pant
Mohan Pant
RBRebecca Brown
Rebecca Brown
JHJaimie Haselhorst
Jaimie Haselhorst
FGFrancine Gagliardotto
Francine Gagliardotto
NANudrat Ayub
Nudrat Ayub
Introduction Home parenteral nutrition (HPN) is essential for patients with intestinal failure requiring long-term nutritional support. The Amerita Quality Improvement Project for HPN Patients (QIP-PN) explored the effect of a physician nutrition expert (PNE)-led multidisciplinary nutritional support team (MNST) on HPN care for patients under its service. Objective To determine an MNST effect on adherence to protocols, outcomes and quality of life (QOL) in HPN. Methods The study was divided into three phases: data review (phases 1a and 1b), observation (phase 2) and intervention (phase 3). Seven Amerita locations were selected as ‘study branches’ (population), from which all study patients and controls were drawn. The quality improvement project employed a quasi-experimental case-matched control group (control) design. Data were collected on demographics, treating physicians PNE status, HPN care variables, recommended interventions, quality-of-life assessment, adverse outcomes and hospitalisations. Paired t-test compared continuous data between phases 2 and 3. Comparisons between study and control groups used a negative binomial regression model. Results Thirty-four patients were reviewed in phase 1a and 197 in phase 1b. Forty study patients completed phase 2 and progressed into phase 3, of whom 30 completed ≥60 therapy days. Patients were lost to follow-up if they discontinued HPN for any reason. Improvements in weight, body mass index and QOL were seen in the study patients during intervention. Recommendations made and accepted by treating physicians differed based on PNE status. Study patients had fewer adverse outcomes and related hospitalisations than controls. Conclusion MNST recommendations improved clinical, biochemical parameters and patients’ self-reported overall health. MNST input reduced adverse outcomes, hospitalisation and the length of stay at the hospital. This study highlights the potential for MNST to have a significant impact on the quality and overall cost of HPN management.

7 June 2021 in Current Developments in Nutrition
Verified
Journal Article
Open access
PDF file
MRMichael Rothkopf
Michael Rothkopf
HBHarold Brem
Harold Brem
TJTom Jacobs
Tom Jacobs
Severe COVID-19 (SvC19) is a syndrome of acute lung injury, respiratory failure, cytokine storm, distributive shock, multi-system organ failure and high mortality. SvC19 disproportionately impacts the elderly, who are also at risk for micronutrient deficiency. After observing a beneficial response to micronutrient repletion (MR) in a 69 year-old male with SvC19, we hypothesized that nutritional deficiencies were linked to the pathogenesis and that correcting them could be beneficial. In this report we detail a case series of 18 older patients with SvC19 treated with MR. All patients had SvC19 requiring mechanical ventilation, elevated levels of CRP, D-dimer and neutrophil to lymphocyte ratio. MR consisted of daily parenteral ascorbate, thiamine, pyridoxine and multivitamins, as well as daily ergocalciferol, zinc and carnitine via nasogastric tube. The average age was 63.3 years. Six patients were male, 12 female. Disease severity was comparable based on SOFA score. A partial response was observed in 10 of the 18 patients (55.5%). Six (33.3%) were able to wean off blood pressure support. Five (27.7%) had improvement in gas exchange. Four (22.2) were able to wean off ventilator support. Three patients (37.5%) showed improvement in renal dysfunction. MR shows potential promise as an adjunctive treatment for severe COVID-19, particularly in older patients or those with chronic illness in whom nutritional deficiencies are more probable. None

1 May 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MRMichael Rothkopf
Michael Rothkopf
Mohan Dev PantMohan Dev Pant
Mohan Dev Pant
ZRZachary S. Rothkopf
Zachary S. Rothkopf
RBRebecca Brown
Rebecca Brown
JHJamie Haselhorst
Jamie Haselhorst
MSMichael Saracco
Michael Saracco
Introduction Although HPN patients often have concomitant medical conditions, little has been done to assess the role of multi-morbidity in relation to HPN care (1-3). A validated method for determining multi-morbidity in HPN patients could be beneficial in determining the needs and risks for each HPN patient. We previously studied the effect of a multidisciplinary nutritional support team (MNST) on quality improvement HPN care (QIP-PN) (4). In a secondary analysis, we explored the options for measuring multi-morbidity of patients in the QIP-PN study. In this report, we describe the results of a pilot study on measuring multi-morbidity in HPN patients to determine its value in HPN care. Objective Determine the role of multi-morbidity scoring in HPN care. Methods 60 HPN patients (30 study patients and 30 case-matched controls) were reviewed for demographics, CIRS Score, number of PN formula changes, hospitalizations and hospital length of stay. Histograms were produced to visually examine the data and cutoffs were selected for CIRS scores based on this information. A matrix plot was drawn showing Spearman correlations among the three variables of interest. The data was then subjected to Kruskal-Wallis and Wilcoxon Rank Sum Tests and Negative Binomial Regression Models to determine if the groups differed significantly. Results 28 patients had CIRS scores <17, while 32 patients had CIRS scores ≥17. The results of negative binomial regression indicate that the number of hospitalizations was a significant predictor of total hospital LOS at the 5% alpha level and that the total hospital LOS of patients with a CIRS Score <17 was significantly different from that of patients with a CIRS≥17 at 5% alpha level. Conclusion We found the CIRS method was well suited to use in HPN patients. It was easy to learn and perform. It provided a single variable which could be used a summary statement of patient multimorbidity. When the CIRS data on 60 long term HPN patients was analyzed, a trend emerged wherein a higher CIRS score was associated with greater hospital LOS. This approach requires greater study and validation. What is already known on this topic?The risk of HPN complications is known to relate to patient demographics, length of functional bowel, duration of HPN therapy and macronutrient content. A validated method for determining multi-morbidity in HPN patients could be beneficial in determining the needs of and risk for each HPN patient. What this study adds The study the explores the role of measuring multi-morbidity scoring in HPN care to determine the risk of adverse effects during therapy. How this study might affect research, practice or policy?The study suggests that using CIRS scoring for HPN patients could help healthcare providers and payors allocate resources based on risk analysis.

14 June 2022 in Current Developments in Nutrition
Verified
Journal Article
Open access
PDF file
MRMichael Rothkopf
Michael Rothkopf
RBRebecca J. Brown
Rebecca J. Brown
ADAndrew DePalma
Andrew DePalma
FGFrancine Gagliardotto
Francine Gagliardotto
JHJamie Haselhorst
Jamie Haselhorst
MSMichael Saracco
Michael Saracco
Introduction. A 97-year-old, 47 kg female with a history of dysphasia, and failed enteral feeding was on HPN for 35 months. PN provided 150 grams dextrose, 75 grams amino acids, electrolytes, MVI and trace elements. Intravenous lipid emulsion (ILE) was held because liver dysfunction and line infections. The patient enrolled in Amerita QIP-PN program. Essential fatty acid and trace element levels were obtained. Severe deficiencies of linoleic (c18:2w6; 524.3; (nl) 2653.4–6130.3 umol/L) and ἀ-linolenic acids (c18:3w3; 4.12; nl 26.1–150.1) were detected. Eicosatrienoic (Mead) acid (c20:3w9) was markedly elevated at 135.33 (nl 10.3–41.3). The eicosatrienoic to arachidonic acid (triene to tetraene) ratio was markedly elevated (0.27; nl 0.02–0.05). Stearic (267.2; nl 590.2 – 1377.2) and arachidic (8.86; nl 16.8 – 38.5) acids were low. Total polyunsaturated (1.6; nl 3.57 – 8.11) and total n-6 fatty acids (1.3; nl 3.3 – 7.1) were low. Seven fatty acid levels were elevated, apparently from de novo lipogenesis in the presence of insulin: myristic = 299.15 (nl 39.4 – 258.2), hexadecanoic = 300.41(nl 19.82 – 59.93), palmetoleic = 1197.60 (nl 68.5 – 570.2), vaccenic = 458.11 (nl 84.82 – 260.8), docosapentanoic = 32.8 (nl 9.2–32.1), docosenoic = 20.88 (nl 5.73 – 11.92). Interventions. Four-oil ILE was added as 20 grams once weekly, providing ∼4 grams of linoleic and ∼0.5 grams of ἀ-linolenic acids. Follow up free fatty acids showed normalization of ἀ-linolenic (27.07) and improvement in linoleic (889.74) and mead (60.34) acids. The triene to tetraene ratio improved to 0.17. An elevated Mead acid level and elevated triene to tetraene ratio confirmed severe EFAD. Mead acid is produced from the elongation of oleic acid (n-9). The n-3, n-6, and n-9 fatty acids all compete for the same desaturases. But the desaturase enzymes have a preference for the fatty acids based on their n-terminal structure. The sequence is n-3 > n-6 > n-9. Therefore, increased Mead acid (20:3n-9) synthesis occurs only with very low availability of n-3 and n-6 fatty acids. In severe EFAD, Mead acid serves as a precursor to specific prostaglandins and leukotrienes via the cycloxygenase and lipoxygenase pathways. This case highlights the value of the QIP-PN in identifying EFAD in long-term HPN patients. None.

8 August 2022
Verified
Book Chapter
Closed access
MRMichael Rothkopf
Michael Rothkopf
JJJennifer C. Johnson
Jennifer C. Johnson
Writing a parenteral nutrition order requires concentration and precision. A stepwise approach can help minimize errors. The process begins with documenting the total volume, infusion rate and access site. Indicate whether or not the infusion is to be cycled within a specific time window. Using data from the patient's estimated nutritional requirements, calculate the macronutrients in total calories and protein. Convert the macronutrient components into grams of amino acids, dextrose and lipids to be entered into the preparation. Order the electrolyte components based on the most recent set of lab data available. Select the appropriate electrolyte salts based on the patient's requirements and acid-base status. Determine if a free water deficit exist and add water as needed. Consider volume restriction if the patient is volume overloaded. Order the vitamin and trace element components based on the likelihood of deficiencies. Review the need for the addition of pharmaceuticals, especially insulin. Before signing the order, estimate the total osmolarity of the formula and confirm that it is appropriate for the venous access site selected.

8 August 2022
Verified
Book Chapter
Closed access
MRMichael Rothkopf
Michael Rothkopf
JJJennifer C. Johnson
Jennifer C. Johnson
When a patient requires long-term nutritional support, the process of transitioning them to homecare therapy must be initiated. The physician nutrition specialist should develop a therapeutic plan, evaluate the homecare organization and perform a medical necessity attestation. A formula transition to cycled infusion is generally utilized. Protocols for monitoring and following-up of the home nutritional support patient should be established.